Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

1.4 Associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease, schistosomiasis ALK-1 indicates activin receptor-like kinase 1; BMPR2, bone morphogenetic ...

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ... Researchers Identify Over 2,000 Genetic Signals Linked to Blood ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

Background: This study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine ... A comprehensive search was conducted using the following terms: (“EGFR-TKI” ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are ... fatigue, hypertension, pain and rash. Concurrent use with docetaxel ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...

You must go to a doctor to know for sure whether you have COPD. That’s because there are things to consider for a diagnosis. Some people have asthma and COPD at the same time. If you have ...